Last reviewed · How we verify
NonQ wave myocardial infarction — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Integrilin | EPTIFIBATIDE | Merck & Co. | Platelet Aggregation Inhibitor [EPC] | Integrin alpha-IIb/beta-3 | 1998-01-01 | |
| integrilin | integrilin | University of Cincinnati | Integrin alpha-IIb/beta-3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck & Co. · 1 drug in NonQ wave myocardial infarction
- University of Cincinnati · 1 drug in NonQ wave myocardial infarction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in NonQ wave myocardial infarction:
- NonQ wave myocardial infarction treatment updates — RSS
- NonQ wave myocardial infarction treatment updates — Atom
- NonQ wave myocardial infarction treatment updates — JSON
Cite this brief
Drug Landscape (2026). NonQ wave myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nonq-wave-myocardial-infarction. Accessed 2026-06-10.
Related
- NonQ wave myocardial infarction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing